LYON, France, January 12, 2023--(BUSINESS WIRE)--Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today its financial calendar for 2023.
March 15, 2023
Publication of 2022 financial statements
April 25, 2023
Publication of revenue for Q1 2023
July 25, 2023
Publication of revenue for Q2 2023
September 18, 2023
Publication of mid-year financial statements as of June 30, 2023
October 25, 2023
Publication of revenue for Q3 2023
In addition to regular meetings with the financial community, investors can also find updated information on the company’s website (www.adocia.com).
All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company’s website, in the Investors’ section, « Regulated Information ».
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on four proprietary technology platforms:
1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells transplantation; 4) AdoGel®, a long-acting drug delivery platform.
Adocia holds more than 25 patent families.
Based in Lyon, the company has about 100 employees. Adocia is listed on the regulated market of EuronextTM Paris (Euronext: ADOC; ISIN: FR0011184241).
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia’s shares in any jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005561/en/
Adocia Press and Investors Relations
email@example.com / + 33 (0)6 64 79 97 51
Margaux Puech Pays d’Alissac
firstname.lastname@example.org / +33 (0)7 86 16 01 09
email@example.com / +33 (0)6 87 88 47 26